Activation of liver X receptor (LXR) enhances de novo fatty acid synthesis in bovine mammary epithelial cells

J. W. McFadden1 and B. A. Corl2
Department of Dairy Science, Virginia Polytechnic Institute and State University, Blacksburg 24061

ABSTRACT

Liver X receptor (LXR) is a nuclear receptor and a known regulator of lipid synthesis in rodents; however, the role of LXR in the regulation of fatty acid synthesis in bovine mammary epithelial cells has not yet been defined. The objective of the study was to evaluate the effect of LXR activation on the de novo synthesis of fatty acids in bovine mammary epithelial cells (BME-UV). Bovine mammary epithelial cells were treated with T0901317 (T09), an LXR agonist. Treatment of BME-UV with T09 increased the transcription of ATP-binding cassette transporter-G1, an LXR target gene, without modifying LXRα mRNA abundance. Acute and chronic treatment of BME-UV with T09 dramatically increased de novo fatty acid synthesis. Activation of LXR resulted in the upregulation of transcription, translation, and proteolytic cleavage of sterol regulatory element-binding protein-1 (SREBP1), a lipogenic transcription factor expressed in the bovine mammary gland. Additionally, the mRNA abundance of fatty acid synthase, an LXR and SREBP1 target gene, increased in response to LXR activation. Our data indicate that SREBP1 is regulated by LXR activation in BME-UV. Controlling LXR activation may prove useful in regulating milk fat production in lactating dairy cows.

Key words: bovine mammary epithelial cell, fatty synthesis, liver X receptor (LXR), sterol regulatory element-binding protein (SREBP)

INTRODUCTION

Liver X receptors (LXR) are nuclear receptors that regulate the synthesis of lipid and control cholesterol homeostasis upon activation by oxysterols or synthetic agonists (Lehmann et al., 1997; Schultz et al., 2000). Liver X receptor-α and LXRβ are 2 known isoforms (Song et al., 1994; Willy et al., 1995), and both regulate the transcription of lipogenic enzymes by binding to DNA in a heterodimeric complex with retinoid X receptor (RXR; Willy et al., 1995). Mice carrying a mutated LXRx gene have decreased expression of acetyl-CoA carboxylase (ACC), fatty acid synthase (FAS), and sterol regulatory element-binding protein-1 (SREBP1), cellular proteins with significant roles in the synthesis of fatty acids (Peet et al., 1998).

Sterol regulatory element-binding protein-1 is a membrane-bound transcription factor that directly regulates the synthesis and uptake of cholesterol and fatty acids (see review by Brown and Goldstein, 1997). The promoters of the lipogenic enzymes ACC, FAS, and glycerol-3-phosphate acyltransferase (GPAT) all contain a sterol response element (SRE) capable of binding SREBP1 (Lopez et al., 1996; Magana and Osborne, 1996; Ericsson et al., 1997). Interestingly, the promoter of SREBP1c contains a liver X response element (LXRE) for LXRx and LXRβ, suggesting the potential for transcriptional regulation of SREBP1c by LXRs (Yoshikawa et al., 2001).

Sterol regulatory element-binding protein-1 is responsive to LXR activation. In rat hepatoma cells, transcription of SREBP1c was stimulated by oxysterols that activate LXRx and LXRβ (DeBose-Boyd et al., 2001). Incubation of human preadipocytes with T0901317 (T09), an LXR agonist, increased abundance of ACC, FAS, and SREBP1c mRNA (Darimont et al., 2006). In wild-type mice, activation of LXR by T09 increased relative amounts of hepatic SREBP1, ACC, FAS, and GPAT mRNA, and this effect was markedly reduced in SREBP1c knockout mice, indicating an essential role of SREBP1c in the LXR response (Liang et al., 2002). In addition to LXR indirectly promoting the transcription of ACC and FAS by increasing the expression of SREBP1c, LXR can increase the transcription of ACC and FAS by binding to an LXRE found within the promoter region of these lipogenic genes (Joseph et al., 2002; Talukdar and Hillgartner, 2006). In SREBP1c knockout mice, Liang and coworkers (2002) observed an increase in ACC and FAS mRNA abundance in response to T09, suggesting a direct effect on ACC and FAS mRNA abundance by LXR.
Sterol regulatory element-binding protein-1 is one of the primary regulators of mammary lipid synthesis as indicated by diet-induced milk fat depression and treatment with conjugated linoleic acid (Harvatine and Bauman, 2006); however, the role of LXR in mammary lipid synthesis is unknown. In dairy cows, expression of LXRα, but not LXRβ, is increased during lactation compared with nonlactating mammary tissue (Harvatine and Bauman, 2007; Mani et al., 2009). In addition, Farke and coworkers (2008) identified the presence of LXRα in bovine mammary tissue, but did not elucidate its role in lipid metabolism. Therefore, our objective was to evaluate the effect of LXR activation on de novo fatty acid synthesis in bovine mammary epithelial cells.

MATERIALS AND METHODS

Cell Culture and Treatments

Chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless noted otherwise. All experiments utilized bovine mammary epithelial (BME-UV) cells (Zavizion et al., 1996). Cells were seeded on plastic cell culture plates at a density of 5 × 10⁵ cells/cm² and cultured at 37°C in 5% CO₂. Cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) with 10 kU/mL penicillin, 10 mg/mL streptomycin, and 25 μg/mL amphotericin B supplemented with 10% fetal bovine serum. Once cells reached confluence, serum was removed and hormones (0.1 μg/mL insulin and 1.5 μg/mL prolactin) were added to the basal media. Cells were cultured in basal media with hormones for 24 h and then treatments were applied.

Cells were treated with T09 (2 μM) for 8 (acute) or 24 h (chronic). In a separate experiment, cells were treated with T09 (2 μM) with or without 10 μM geranylgeranyl pyrophosphate (GGPP) for 24 h. Dimethyl sulfoxide served as control when evaluating the effects of T09 or GGPP. Cells were treated with 0.4% dimethyl sulfoxide or less.

Sample Analysis

De novo fatty acid synthesis was determined by quantifying the incorporation of [1-14C]-labeled acetate into lipid after 8 or 24 h of treatment. Activity was calculated and expressed as picomole of acetate incorporated per microgram of DNA. Methods for fatty acid synthesis and DNA quantification were adapted from McFadden and Corl (2009).

Total RNA was extracted from cultured cells using TRI Reagent (Molecular Research Center Inc., Cincinnati, OH) according to the manufacturer’s instructions. Ribonucleic acid pellets were resuspended in RNase-free water and quantified at 260 nm using a spectrophotometer. Total RNA (500 ng per reaction) was reverse transcribed into cDNA using the Omniscript reverse transcription kit (Qiagen, Valencia, CA) according to the manufacturer’s instructions using oligo(dT) (Roche Applied Science, Indianapolis, IN) as the primer.

Real-time PCR reactions were performed using the Quantitect SYBR Green PCR kit (Qiagen) and an Applied Biosystems 7300 Real-time PCR machine (Applied Biosystems, Foster City, CA). Quantification of gene transcripts for LXRα, ATP-binding cassette transporter-G1 (ABCG1), cytochrome P4501A1 (Cyp1A1), SREBP1, insulin-induced gene-1 (INSIG1), insulin-induced gene-2 (INSIG2), and FAS was completed using gene-specific primers. GenBank accession numbers for primers are included in Table 1. The cycle threshold (Ct) values for β-actin were not statistically different between treatments or sets; therefore, β-actin was used as the endogenous control gene. Reaction conditions were as follows: 1 cycle at 95°C for 10 min followed by 40 cycles at 95°C for 24 s, 58°C for 24 s, and 72°C for 1 min.

Table 1. Summary of genes, primers, and product sizes

<table>
<thead>
<tr>
<th>Target gene</th>
<th>Forward primer (5′-3′)</th>
<th>Reverse primer (3′-5′)</th>
<th>Intron-spanning</th>
<th>Size (bp)</th>
<th>GenBank accession number</th>
</tr>
</thead>
<tbody>
<tr>
<td>LXRα</td>
<td>TCAACCCCATTTCTCGAGTTC</td>
<td>ACGACTACTTTTGACACCTCG</td>
<td>Yes</td>
<td>232</td>
<td>NM_001014861</td>
</tr>
<tr>
<td>ABCG1</td>
<td>GACTCGGTCTCTAGCCGAC</td>
<td>CGGAGAAACACGCTCTCAGTC</td>
<td>Yes</td>
<td>203</td>
<td>XM_587930</td>
</tr>
<tr>
<td>Cyp1A1</td>
<td>CCGACCTCTACAGCTTTACC</td>
<td>CTTGGGCTCTTGTTCCTCAT</td>
<td>No</td>
<td>185</td>
<td>AB060996</td>
</tr>
<tr>
<td>SREBP12</td>
<td>ATGCCATGGAGAAGCGCTAC</td>
<td>CTCTTGGACTACAGCGCTTG</td>
<td>Yes</td>
<td>180</td>
<td>NM_214157</td>
</tr>
<tr>
<td>INSIG1</td>
<td>GTCATTGCAACCTTCTCCTTC</td>
<td>AGTGGAACTCTCGGTGTGTT</td>
<td>Yes</td>
<td>115</td>
<td>XM_589325</td>
</tr>
<tr>
<td>INSIG2</td>
<td>TCCAGTTGATGGCGGGTGTTA</td>
<td>AGTGGTACGCGAGTGATAGTT</td>
<td>Yes</td>
<td>108</td>
<td>XM_614207</td>
</tr>
<tr>
<td>FAS</td>
<td>AACACACATCGGCGGAAAGGT</td>
<td>TGTAAGCGTCCATTGTAAGTA</td>
<td>No</td>
<td>152</td>
<td>NM_001012669</td>
</tr>
<tr>
<td>β-actin</td>
<td>CTCTTCCAGCCTTCTCTCTCTC</td>
<td>CGTCTTTCTCAGCGGCAAGGG</td>
<td>Yes</td>
<td>178</td>
<td>AY141970</td>
</tr>
</tbody>
</table>

1LXRα = liver X receptor-α; ABCG1 = ATP-binding cassette transporter-G1; Cyp1A1 = cytochrome P4501A1; SREBP1 = sterol regulatory element-binding protein-1; INSIG1 = insulin-induced gene-1; INSIG2 = insulin-induced gene-2; FAS = fatty acid synthase.

2Primer pairs do not distinguish between SREBP1a and SREBP1c isoforms.
For determination of premature and mature SREBP1 (pSREBP1 and mSREBP1, respectively) proteins, BME-UV cells were harvested and processed as described previously by DeBose-Boyd et al. (1999) with the following modifications. Briefly, cells were harvested in media from two 100-mm cell culture dishes and centrifuged at 250 × g for 5 min at 4°C. The supernatant was removed and cells were washed with ice-cold PBS and centrifuged at 250 × g for 5 min at 4°C. The cell pellet was resuspended in 0.6 mL of buffer A (10 mM HEPES-KOH at pH 7.6, 10 mM KCl, 1.5 mM MgCl₂, 1 mM sodium EDTA, 250 mM sucrose, and protease inhibitor cocktail), passed through a 25-gauge needle 25 times, and centrifuged at 1,000 × g for 5 min at 4°C. The resulting pellet was resuspended in 0.1 mL of buffer B (20 mM HEPES-KOH at pH 7.6, 2.5% vol/vol glycerol, 0.42 M NaCl, 1.5 mM MgCl₂, 1 mM sodium EDTA, and protease inhibitor cocktail), and then centrifuged at 4°C for 1 h, and centrifuged at 100,000 × g for 15 min at 4°C. The supernatant from this centrifugation was designated the nuclear extract. The supernatant from the original 1,000 × g spin was used to prepare the membrane fraction by centrifugation at 10,000 × g for 15 min at 4°C. The resulting membrane pellets were resuspended in 0.1 mL of ice-cold lysis buffer (50 mM Tris pH 7.4, 0.5% Triton X-100, 0.3 M NaCl, 2 mM EDTA, and protease inhibitor cocktail).

Nuclear and membrane extracts were assayed for protein concentration using the Bradford assay (Bio-Rad, Hercules, CA) and then diluted to the same protein concentrations with Laemmli sample buffer (Bio-Rad) and heated at 95°C for 7 min. Proteins were separated by SDS-PAGE, transferred to polyvinylidene fluoride membranes, blocked with 5% dried nonfat milk in Tris-buffered saline–TWEEN, and incubated with anti-SREBP-1 primary antibody (sc-13551, Santa Cruz Biotechnology, Santa Cruz, CA). Bound antibodies were detected with horseradish peroxidase-linked secondary antibodies and detected using chemiluminescence (ECL-Plus, Amersham Biosciences, Pittsburgh, PA). Chemiluminescence was measured using a Chemidoc XRS digital imaging system. Luminescence was quantified using Quantity One software (Bio-Rad) and expressed as net intensity (arbitrary units).

**Statistical Analysis**

All data were analyzed using the Mixed procedure of SAS (SAS 9.1, SAS Institute Inc., Cary, NC). Abundance of pSREBP1 or mSREBP1 in BME-UV was analyzed according to the model Y_{ijkl} = μ + T_i + S_j + (T × S)_{ij} + ε_{ijkl}, where Y_{ijkl} is the individual observation, μ is the overall mean, T_i is the fixed effect of treatment (i = 1, and 2), S_j is the fixed effect of set (j = 1, and 2), and ε_{ijkl} is the residual error term. The model Y_{ijkl} = μ + T_i + S_j + (T × S)_{ij} + ε_{ijkl} was used to analyze all other data, where (T × S)_{ij} is the fixed effect of the interaction between treatment and set, R_{ijk} is the random effect of replicate within set (k = 1, 2, and 3), and ε_{ijkl} is the residual error term. One well represents 1 individual observation. Treatments include the presence of T09 and GGPP. Treatments were performed in triplicate wells per independent experiment unless otherwise noted. One set represents 1 independent experiment and each set differed in cell passage number. Results did not differ across sets and data were pooled. If a significant treatment effect was observed, Tukey’s multiple comparison procedure was used to separate treatment means. Real-time PCR data were analyzed using transcript Ct values normalized with β-actin as the endogenous control gene (ΔCt). For the purpose of presentation, least squares means are illustrated as fold change relative to control using the 2^{−ΔΔCt} method (Livak and Schmittgen, 2001).

**RESULTS AND DISCUSSION**

The function of LXRs in the bovine mammary gland is undefined. In dairy cows, expression of LXRα, but not LXRβ, is increased during lactation compared with nonlactating mammary tissue (Harvatine and Bauman, 2007). To our knowledge, the activation of LXRα in BME-UV has not been investigated before this experiment.

**T09 Is an Effective LXR Agonist**

Nuclear receptors such as LXR undergo a conformational change upon ligand binding that promotes their activity. T0901317 is a synthetic, nonsteroidal compound and a highly potent, selective LXRα ligand (Schultz et al., 2000). In addition, T09 increases LXR activity without modifying LXR expression (Houck et al., 2004). In agreement with previously published data, LXRα mRNA abundance was unaffected by acute or chronic treatment with T09 in BME-UV (Figure 1). Moreover, ATP-binding cassette transporter-G1 and Cyp1A1 are known LXR target genes and are upregulated in response to T09 (Dressel et al., 2003; Westerink and Schoonen, 2007). The ATP-binding cassette transporter-G1 has been implicated in the efflux of cholesterol to high-density lipoprotein (Wang et al., 2004). Recently, the presence of ABCG1 was verified in the bovine mammary gland (Farke et al., 2008). In response to acute and chronic treatment with T09, ABCG1 mRNA abundance increased (P < 0.001) 11- and 43-fold, respectively (Figure 1). Cytochrome P4501A1 was unresponsive to T09 (Figure 1). Mani
and coworkers (2009) compared the expression of lipid transporters and regulators in the mammary glands of dairy cows between the dry period and early lactation. Their results demonstrated a significant increase in LXRα mRNA abundance in conjunction with the onset of lactation. Additionally, they observed a positive correlation between the mRNA abundance of ABCG1 and LXRα, suggesting that LXRα regulates ABCG1 in the bovine mammary gland. We conclude that LXR is present in BME-UV mammary epithelial cells and elicits a prototypical response to treatment with T09. In addition, activation of LXR may serve as a potential regulator of cholesterol homeostasis in the bovine mammary gland.

**LXR Activation Increases De Novo Fatty Acid Synthesis**

Liver X receptors regulate the synthesis of lipids including cholesterol, bile acids, and fatty acids. Liver X receptor-α is a major sensor of dietary cholesterol and functions as an important transcriptional control point in bile acid synthesis (Peet et al., 1998). The ability of LXR to regulate fatty acid synthesis has also been demonstrated. Peet and coworkers (1998) found that mice carrying a targeted disruption of the LXRα gene had decreased expression of ACC, FAS, stearoyl-CoA desaturase-1, and SREBP1. Furthermore, oral administration of T09 to C57BL/6 mice resulted in the up-regulation of lipogenic enzyme expression and increased plasma triacylglycerol levels (Schultz et al., 2000). In the present study, acute and chronic treatment with 2 μM T09 increased (P < 0.001) de novo fatty acid synthesis in BME-UV by 38 and 60%, respectively (Figure 2). Treatment of BME-UV with T09 concentrations greater than 2 μM resulted in cell death (our unpublished data). Geranylgeranyl pyrophosphate is an LXR antagonist that decreases the transcription of LXR target genes (Gan et al., 2001). Chronic treatment of BME-UV with GGPP failed to reverse the T09-induced increase in de novo fatty acid synthesis (Figure 2B).
In human monocytic leukemia and intestinal epithelial cell lines, Gan and coworkers (2001) demonstrated the ability of GGPP to antagonize LXR. They concluded that GGPP could directly antagonize LXR by reducing the interaction between LXR and steroid receptor coactivator-1, a nuclear coactivator. It is currently not known if steroid receptor coactivator-1 is expressed and functional in the bovine mammary gland. Bovine mammary gland LXR may not depend on steroid receptor coactivator-1 for activation or LXR may interact with a different coactivator. Geranylgeranyl pyrophosphate may be unable to inhibit LXR in BME-UV because of these unknown factors. Regardless of these unknowns, the lipogenic response to T09 was rapid and was sustained over a 24-h period.

**LXR Activation Increases SREBP1 mRNA and Protein Abundance**

Activation of LXR by T09 enhances the expression of SREBP1 (Repa et al., 2000). Repa et al. (2000) concluded that cholesterol-derived oxysterols activate LXR to induce expression of the mouse SREBP1c gene through an LXRE located within its proximal promoter. In addition, the SREBP1a and SREBP2 isoforms were unresponsive to LXR activation by T09 (Schultz et al., 2000; DeBose-Boyd et al., 2001). The expression of SREBP1 has been shown to be significantly upregulated during lactation in mice and cows and is considered the primary regulator of milk fat synthesis (Bionaz and Loor, 2008). In the present study, acute and chronic treatment of BME-UV with T09 increased (\(P < 0.001\)) the mRNA abundance of SREBP1 by 255 and 416%, respectively (Figure 3). We also observed an increase (\(P < 0.10\)) in protein abundance for pSREBP1 and mSREBP1 in response to 8-h treatment with T09 (Figure 4). This may indicate that LXR is acting globally to increase lipogenesis through SREBP1. Diet-induced milk fat depression is characterized by a reduction in mammary expression of SREBP1 (Harvatine and Bau- man, 2006); therefore, activating LXR and increasing SREBP1 protein abundance could reverse the inhibi-
tory effect of low-fiber, high-concentrate diets on milk fat synthesis.

Insulin-induced gene-1 and INSIG2 are integral membrane proteins that cause retention of SREBP1 in the endoplasmic reticulum, preventing SREBP1 activation. Interestingly, the INSIG1 promoter can be regulated by transcriptionally active SREBP1 (Kast-Woelbern et al., 2004). Overexpression of INSIG1 in the livers of transgenic mice inhibits SREBP1 processing and reduces insulin-stimulated lipogenesis (Engelking et al., 2004). In the present study, the mRNA abundance of INSIG1 was unaffected by acute treatment with T09 (Figure 3A); however, chronic treatment of BME-UV with T09 increased \((P < 0.001)\) the mRNA abundance of INSIG1 (Figure 3B). Chronic treatment with T09 may have lessened the proteolytic cleavage of pSREBP1 by promoting the development of a negative feedback response through increased INSIG1 expression. Therefore, maximum increases in fatty acid synthesis in response to chronic T09 may have been reduced by feedback inhibition. The mRNA abundance of INSIG2 was unaffected by acute or chronic treatment with T09 (Figure 3), indicating that this effect may be unique to the INSIG1 isoform. We conclude that it is possible that INSIG1 retained a portion of pSREBP1 within the endoplasmic reticulum, possibly dampening the ability of T09 to increase de novo lipogenesis over a 24-h period.

**LXR Activation Increases FAS mRNA Abundance**

Fatty acid synthase is a known SREBP1 target gene and an essential enzyme in the de novo synthesis of fatty acids (Magana and Osborne, 1996; Harvatine and Bauman, 2006). In human preadipocytes, the mRNA abundance of FAS and SREBP1c is increased in response to T09 (Darimont et al., 2006). In the present study, acute and chronic treatment with T09 increased \((P < 0.001)\) FAS mRNA abundance by 89 and 185%, respectively (Figure 3). This may indicate the indirect involvement of SREBP1 because the FAS promoter contains tandem SREBP1c binding sites (Joseph et al., 2002). Alternatively, LXR may act directly by binding to LXR/RXR binding sites found within the FAS promoter (Joseph et al., 2002). Joseph and coworkers (2002) confirmed that maximum induction of FAS requires both LXR and SREBP1c binding to their respective response elements within the promoter region. Therefore, treatment of BME-UV with T09 most likely increased FAS abundance by increasing SREBP1 and LXR binding, resulting in maximum activation. Whether or not SREBP1 and LXR acted in concert or independent of each other remains to be determined. Further examination of the activation of the FAS promoter will be required to resolve this uncertainty. Additionally, bioinformatic examination of the promoters of other lipogenic genes in the bovine genome may reveal LXRE sites that regulate transcription. We conclude that acute and chronic activation of LXR increased de novo fatty acid synthesis in BME-UV. Additionally, we observed an increase in SREBP1 and FAS abundance in response to LXR activation. It remains to be determined whether LXR directly or indirectly regulates FAS abundance.

**CONCLUSIONS**

Liver X receptor regulates the de novo synthesis of fatty acids in BME-UV by promoting the transcription of SREBP1 and FAS. Activation of LXR by T09 may prove to be a useful tool in identifying the relative contributions of LXRxα and SREBP1 toward the overall synthesis of fatty acids in the bovine mammary gland.
Controlling the activation of LXR in the mammary gland of the lactating dairy cow may give producers the ability to modify milk fat production to meet consumer demand.

ACKNOWLEDGMENTS

This project was supported by National Research Initiative Competitive Grant no. 2009 35204 05358 from the USDA National Institute of Food and Agriculture (Washington, DC).

REFERENCES


Harvatine, K. J., and D. E. Bauman. 2006. SREBP1 and thyroid hormone responsive Spot 14 (S14) are involved in the regulation of bovine mammary lipid synthesis during diet-induced milk fat depression and treatment with CLA. J. Nutr. 136:2468-2474.

Harvatine, K. J., and D. E. Bauman. 2007. Expression of PPAR and LXR nuclear hormone receptor families are not modified during milk fat depression induced by diet or treatment with trans-10, cis-12 conjugated linoleic acid (CLA). J. Dairy Sci. 90(Suppl. 1):59. (Abstr.)


Talukdar, S., and F. B. Hillgartner. 2006. The mechanism mediating the activation of acetyl-coenzyme A carboxylase-α gene transcription by the liver X receptor agonist T0–901317. J. Lipid Res. 47:2451-2461.


